Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5421745 | 0.85 | ESR2 (1.00) | ESR1ESR2 | |
| SCHEMBL5425066 | 0.84 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL5428947 | 0.82 | ESR2 (1.00) | ESR1ESR2 | |
| SCHEMBL14547497 | 0.80 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL5582284 | 0.78 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL5428232 | 0.78 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL5582352 | 0.76 | ESR1 (0.52) | ESR1ESR2 | |
| SCHEMBL5424359 | 0.75 | ESR2 (1.00) | ESR1ESR2 | |
| SCHEMBL1658311 | 0.74 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL5439859 | 0.73 | ESR2 (0.76) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087346-A1 | Orthogonal gene switches | TCF12, JUN, TCF7 | ESR1 329/4885ESR2 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.